News

UCB net profit was EUR103m for the full-year of 2010, compared to EUR513m for the same period in 2009. Net sales for the full-year of 2010 were EUR2.78bn,

As per the agreement, Charles River is expected to take up the responsibility for supplying the research models throughout a range of therapeutic areas like neuroscience, diabetes and

With the new design, the company’s familiar brands including Kendall, Valleylab, Mallinckrodt and Nellcor are shown under the Covidien name. The new Covidien packaging will be standardized throughout

With this approval Bristol-Myers Squibb get marketing authorization right for Baraclude in 27 countries of the European Union. According to the company, the approval is based on a

Perrigo is a global healthcare supplier engaged in developing, manufacturing and distributing OTC and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, active pharmaceutical ingredients (API) and pharmaceutical

The study is a 19-week follow-up, multicentre, double-blind, randomised, placebo-controlled, parallel-group study in subjects with MS spasticity not fully relieved with current anti-spasticity therapy. The trial result suggested

Nektar has posted a net loss of $22.58m for the fourth quarter of 2010, compared to net loss $7.68m for the same period in 2009.The company’s loss from

L-DOS47 is intended to offer an innovative approach to the first-line treatment of inoperable, locally advanced, recurrent or metastatic NSCLC. According to Helix, L-DOS47 will stimulate an increase

ERT has posted gross margin of $19.71m for the fourth quarter of 2010, compared to $13.17m for the same period in 2009. The company has generated net income